{"id":"NCT03158220","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)","officialTitle":"An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-20","primaryCompletion":"2018-11-19","completion":"2018-11-19","firstPosted":"2017-05-18","resultsPosted":"2019-11-21","lastUpdate":"2019-11-21"},"enrollment":1212,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Cervical Cancer","Vulvar Cancer","Vaginal Cancer","Genital Warts","Human Papillomavirus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"V503","otherNames":["GARDASIL®9 (HPV 9-valent vaccine [recombinant, adsorbed]); HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58"]}],"arms":[{"label":"Adult Women 27- to 45-years Old","type":"EXPERIMENTAL"},{"label":"Young Adult Women 16- to 26-years Old","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4 weeks postdose 3 are non-inferior in adult women as compared with GMTs in young adult women.","primaryOutcome":{"measure":"Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type","timeFrame":"4 weeks post vaccination 3 (Month 7)","effectByArm":[{"arm":"Women 16-26 Years of Age","deltaMin":787.8,"sd":null},{"arm":"Women 27-45 Years of Age","deltaMin":638.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"16 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":10},"locations":{"siteCount":24,"countries":["Austria","Belgium","Finland","Germany","Italy","Spain"]},"refs":{"pmids":["33676783"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":570},"commonTop":["Injection site pain","Headache","Injection site swelling","Injection site erythema","Nasopharyngitis"]}}